Table 2.
Genotype effect on serum C-reactive protein level and Disease Activity Score in 28 joints at baseline and year 1 a
| Baseline CRP | Year 1 CRP | Baseline DAS28 | Year 1 DAS28 | |||||
|---|---|---|---|---|---|---|---|---|
| SNP | β | P -value | β | P -value | β | P -value | β | P -value |
| rs11265257 | −0.14 | 0.19 | −0.01 | 0.91 | −0.09 | 0.31 | −0.06 | 0.49 |
| rs1130864 | 0.15 | 0.21 | 0.03 | 0.78 | 0.16 | 0.10 | 0.14 | 0.12 |
| rs1205 | −0.26 | 0.03 | −0.09 | 0.38 | −0.08 | 0.39 | −0.09 | 0.32 |
| rs1800947 | −0.34 | 0.14 | −0.12 | 0.57 | 0.02 | 0.91 | 0.23 | 0.21 |
| rs2808632 | 0.18 | 0.15 | −0.04 | 0.73 | −0.04 | 0.71 | −0.08 | 0.40 |
| rs3093077 | −0.10 | 0.69 | 0.30 | 0.16 | −0.26 | 0.21 | −0.02 | 0.90 |
| rs876538 | 0.15 | 0.28 | −0.05 | 0.66 | 0.02 | 0.86 | −0.02 | 0.87 |
aLinear regression analysis with age, sex and treatment as covariates. CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; SNP, Single-nucleotide polymorphism.